SCHEMBL6017903

SCHEMBL6017903

COc1ccc(-c2nc(C(=O)NCc3ccc(C)c(C)c3)c(O)c(=O)n2C)cn1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 1/20 0.44
GSK3B P49841 1/20 0.44
HDAC1 Q13547 1/20 0.43
EGLN1 Q9GZT9 2/20 0.42
ADORA2A P29274 3/20 0.41
ADORA2B P29275 2/20 0.40
PTGES O14684 3/20 0.40
KCNE1 P15382 1/20 0.40
CCR1 P32246 1/20 0.40
KCNQ1 P51787 1/20 0.40
CHRM4 P08173 1/20 0.40
SCD O00767 1/20 0.39
TP53 P04637 1/20 0.39
MAPT P10636 1/20 0.39
SMO Q99835 1/20 0.39
PIK3CA P42336 1/20 0.38
TSHR P16473 1/20 0.38
PDE5A O76074 1/20 0.38
PDE6A P16499 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6018646 0.89 PTGES (0.46) CDK2GSK3BHDAC1EGLN1PTGES
SCHEMBL6018074 0.88 KCNE1 (0.51) CDK2GSK3BHDAC1EGLN1ADORA2A
SCHEMBL6018601 0.88 TP53 (0.51) CHRM4SCDTP53MAPT
SCHEMBL6017795 0.83 MMP1 (0.50) EGLN1KCNE1CCR1KCNQ1
SCHEMBL6017674 0.83 SMN1; SMN2 (0.42) GSK3BEGLN1KCNE1CCR1KCNQ1
SCHEMBL6017668 0.83 MEN1 (0.47) GSK3BCHRM4TP53MAPT
SCHEMBL6018457 0.82 EGLN1 (0.47) EGLN1TP53MAPT
SCHEMBL6017934 0.80 TSHR (0.46) ADORA2AKCNE1CCR1KCNQ1MAPT
SCHEMBL6018060 0.80 TSHR (0.47) HDAC1ADORA2AKCNE1CCR1KCNQ1
SCHEMBL6017994 0.78 KCNE1 (0.43) KCNE1CCR1KCNQ1MAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040229892-A1 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex BRISTOL-MYERS SQUIBB COMPANY 2004-11-18 US claimed
US-7037908-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2006-05-02 US disclosed
US-20040229892-A1 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex BRISTOL-MYERS SQUIBB COMPANY 2004-11-18 US disclosed
WO-2004096128-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229892-A1 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex DUT, CDK6, TYMS CDK2 22/4885GSK3B 2860/4885HDAC1 148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.